| Name | Title | Contact Details |
|---|---|---|
Claudia Kuri |
Chief Operating Officer | Profile |
Glenn Galloway |
Executive VP Technology & Integrations | Profile |
The Federation of American Hospitals (FAH), founded in 1966, is the national representative of investor-owned or managed community hospitals and health systems throughout the United States and one of Washington, DC`s most respected and influential health policy and advocacy organizations. Dedicated to a market-based philosophy, we provide representation and advocacy on behalf of our members to Congress, the Executive Branch, the judiciary, media, academia, accrediting organizations and the public. The Federation of American Hospitals serves its members as a clearinghouse for information about the nation`s most vital health policy issues. These include Medicare and Medicaid, the uninsured, health care quality, patient safety, health information technology, medical liability insurance reform, rural health care, long-term hospital care, inpatient psychiatric care, hospital emergency preparedness, antitrust, compliance, the health care workforce shortage, privacy and confidentiality, tax issues, and rehabilitation services, among other important issues.
A regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. Two product families - a proprietary liquid complex of embryonic-like proteins and growth factors` and a human Extracellular Matrix (ECM) material` ExCeltrix..
Anatomical Chart Company is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Troy Medicare started in Concord, North Carolina with several pharmacists seeing people increasingly unable to afford their prescriptions. Health plans had become more expensive and less transparent in their drug pricing.